Leerink Partnrs Brokers Lower Earnings Estimates for ORKA

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for Oruka Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of ($1.56) per share for the year, down from their prior forecast of ($1.33). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at ($1.96) EPS and FY2027 earnings at ($1.99) EPS.

A number of other equities analysts also recently weighed in on ORKA. Stifel Nicolaus began coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. TD Cowen initiated coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Thursday, October 31st. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Leerink Partners initiated coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Trading Up 0.2 %

Shares of NASDAQ ORKA opened at $24.04 on Monday. The stock’s 50 day simple moving average is $26.76. The firm has a market capitalization of $29.09 million, a P/E ratio of -3.84 and a beta of 0.87. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors have recently made changes to their positions in ORKA. Geode Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $343,000. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $1,037,000. Wellington Management Group LLP bought a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $2,013,000. Janus Henderson Group PLC bought a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $5,840,000. Finally, Redmile Group LLC bought a new stake in shares of Oruka Therapeutics in the third quarter valued at approximately $10,091,000. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.